论文部分内容阅读
目的:研究冠心病患者血清内脂素水平的变化以及辛伐他汀治疗对其水平的影响。方法:选取78例合并轻度血脂升高冠心病患者和62名健康对照者,检测2组的血清内脂素水平有无差异。78例冠心病患者再进一步随机分为常规治疗组和辛伐他汀组,每组39例,观察2组在治疗前后血清内脂素水平的变化。结果:与正常对照组相比,冠心病患者的血清内脂素水平显著升高,差异有统计学意义。血清内脂素与体重指数、收缩压、空腹血糖、胰岛素抵抗指数和三酰甘油呈正相关,而与高密度脂蛋白胆固醇呈负相关。治疗4周后,辛伐他汀组的血清内脂素水平较治疗前明显下降,差异有统计学意义;而常规治疗组的血清内脂素水平无明显变化,差异无统计学意义。结论:辛伐他汀具有降低冠心病患者血清内脂素的作用。
Objective: To study the change of serum visfatin level in patients with coronary heart disease and the effect of simvastatin on its level. Methods: Seventy-eight patients with coronary heart disease and 62 healthy controls were enrolled in the study. There was no difference in serum visfatin levels between the two groups. 78 patients with coronary heart disease were further randomly divided into routine treatment group and simvastatin group, 39 cases in each group. The changes of serum visfatin in two groups before and after treatment were observed. Results: Compared with the normal control group, serum visfatin levels were significantly increased in patients with coronary heart disease, the difference was statistically significant. Serum visfatin was positively correlated with body mass index, systolic blood pressure, fasting blood glucose, insulin resistance index and triglyceride, but negatively with high density lipoprotein cholesterol. Four weeks after treatment, the level of serum visfatin in the simvastatin group was significantly lower than that before treatment, and the difference was statistically significant. However, the serum level of visfatin did not change significantly in the routine treatment group, with no significant difference. Conclusion: Simvastatin can reduce the serum visfatin in patients with coronary heart disease.